Repare Therapeutics Inc.
RPTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 4.6% | -61.2% | 1,634.6% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 75% | 74.1% | 11.5% | -1,056% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -168.7% | -223.5% | -13.5% | -1,410.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -158.4% | -183.4% | -22% | -1,406.7% |
| EPS Diluted | -2 | -2.23 | -0.69 | -2.83 |
| % Growth | 10.3% | -223.2% | 75.6% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |